The Delta variant, widespread in India and more transmissible, is the one that is most worrying European countries, as they see how it spreads in a time scheduled for de-escalation. The United Kingdom is one of the countries most affected by the new strain. And, in addition, its vaccination strategy has been focused on AstraZeneca, which offers less effectiveness compared to Delta.
How effective is AstraZeneca compared to Pfizer
The public health body Public Health England (PHE) explained that the vaccines against Covid-19 manufactured by the coronavirus. However, while Pfizer offers 88% effectiveness, AstraZeneca does so at 60%. The effectiveness of these vaccines against the British variant, another of the most widespread, is 93% (Pfizer) and 63% (AstraZeneca).
Furthermore, both preparations provided 33% effectiveness against symptomatic disease against the Indian variant three weeks after the first dose, compared to approximately 50% against the British variant. According to these data, in the case of the AstraZeneca vaccine, more time is needed for the preparation to reach its maximum effectiveness.
AstraZeneca’s vaccine generates fewer antibodies to Delta
Given the increase in the number of hospitalizations in the United Kingdom due to the advancement of the Delta variant, a British team of researchers has published in The Lancet journal a The results showed that the neutralizing antibody response of AstraZeneca was 2.5 times lower compared to the Indian variant.
This conclusion has been reached through the analysis of in vitro tests with serum from people with a complete vaccination schedule. However, the authors assure that these results agree with those that are being registered with the circulation of the different variants in the United Kingdom.
A third dose of AstraZeneca
Given this advance of the Delta variant, a recent study prepared by the University of Oxford and published in The Lancet has pointed out that injecting the increase in antibodies, an enhancement of the T cell response and the immune response against variants.
“Whether booster injections will be needed due to decreased immunity or to increase immunity against variants of concern is not known,” says Associate Professor Teresa Lambe OBE, lead senior author of these studies. “Here we show that a third dose of ChAdOx1 nCoV-19 (AstraZeneca’s vaccine against the Covid-19 virus) is well tolerated and significantly increases the antibody response. This is very encouraging news, if we find that a third dose.”
Facebook Comments
Disqus